ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0167

Healthcare Resource Utilization Associated with Tumor-Induced Osteomalacia: Review of Patient Histories Prior to Entry in Clinical Trial UX023T-CL201

Suzanne Jan de Beur1, Thomas Carpenter2, Kathryn Dahir3, Erik Imel4, María Belén Zanchetta5, Angela Williams6, Zhiyi Li7, Matthew Sharp6 and Ben Johnson6, 1Johns Hopkins University School of Medicine, Baltimore, MD, 2Yale School of Medicine, New Haven, CT, 3Vanderbilt University Medical Center, Nashville, TN, 4Indiana University School of Medicine, Indianapolis, IN, 5Universidad del Salvador, Buenos Aires, Argentina, 6Kyowa Kirin International, Marlow, United Kingdom, 7Kyowa Kirin North America, Bedminster, NJ

Meeting: ACR Convergence 2023

Keywords: Fracture, Health Care, Imaging, Musculoskeletal Examination, Orthopedics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 12, 2023

Title: (0155–0175) Health Services Research Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Tumor-induced osteomalacia (TIO) is an ultra-rare paraneoplastic disorder, characterized by renal phosphate wasting due to increased production of fibroblast growth factor 23 (FGF23). Chronic hypophosphatemia causes the accumulation of severe musculoskeletal morbidities, and delays in diagnosis are common, which can lead to considerable healthcare resource use (HCRU). The objective of this study is to estimate HCRU from histories of adults with TIO not curable by surgery, prior to enrollment in the UX023T-CL201 burosumab phase 2 trial.

Methods: Histories of the 14 TIO patients enrolled in UX023T-CL201 were assessed independently by two reviewers. Data related to clinical events directly associated with HCRU were extracted and categorized.

Results: Mean age of TIO subjects enrolled in the trial was 56.9 ± 10.3 years (range 33-68); 57% (8) were male. Mean time between first symptoms and TIO diagnosis was 4.2 ± 4.1 years (range 0.1-13.2); mean time since diagnosis was 13.7 ± 13.0 years (range 0.7-35.8). Tumors were identified in 71% (10) patients, with surgical removal attempted in 64% (9).

Subjects underwent a mean of 11.1 ± 13.2 tumor investigations (range 1-46). The most frequent were magnetic resonance imaging (mean 4.9 ± 7.5 per patient; range 0-29), positron emission tomography/computed tomography (mean 1.9 ± 5.3; range 0-20), octreotide scan (mean 1.4 ± 2.3; range 0-7), and computed tomography (mean 1.3 ± 1.8; range 0-5).

All patients had a history of active vitamin D treatment, and 93% (13) had a history of oral phosphate treatment, with a mean duration of 10.4 ± 12.5 (range 0.3-35.0) and 10.5 ± 12.2 years (range 1.2-35.0), respectively.

History of fracture was reported in 93% (13) patients, with a mean of 5.4 ± 6.8 fractures per patient (range 0-28). The most frequently reported fracture locations were the ribs (mean 1.6 ± 3.3 fractures; range 0-13), foot/ankle (mean 1.0 ± 2.1; range 0-8), and femur (mean 0.7 ± 0.9; range 0-2).

Orthopedic procedures included spinal laminectomy in 21% (3) subjects, spinal corpectomy in 14% (2) subjects, and hip and knee arthroplasty in 14% (2) subjects each.

Conclusion: TIO is associated with substantial HCRU resulting from diagnosis, attempted tumor localization/removal, and disease management.


Disclosures: S. Jan de Beur: Amgen, 2, Ascendis Pharma, 2, Inozyme Pharma, 2, Kyowa Kirin, 2, Mereo BioPharma, 5, Ultragenyx, 2, 5; T. Carpenter: Kyowa Kirin, 2, Ultragenyx, 2, 5, Viridian Therapeutics, 2; K. Dahir: Alexion/AstraZeneca, 2, 5, Ultragenyx, 2, 5; E. Imel: Kyowa Kirin, 2, Ultragenyx, 2, 5; M. Belén Zanchetta: Adium, 2, Amgen, 2, Ultragenyx, 2; A. Williams: Kyowa Kirin International, 3; Z. Li: Kyowa Kirin North America, 3; M. Sharp: Kyowa Kirin International, 3; B. Johnson: Kyowa Kirin International, 3.

To cite this abstract in AMA style:

Jan de Beur S, Carpenter T, Dahir K, Imel E, Belén Zanchetta M, Williams A, Li Z, Sharp M, Johnson B. Healthcare Resource Utilization Associated with Tumor-Induced Osteomalacia: Review of Patient Histories Prior to Entry in Clinical Trial UX023T-CL201 [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/healthcare-resource-utilization-associated-with-tumor-induced-osteomalacia-review-of-patient-histories-prior-to-entry-in-clinical-trial-ux023t-cl201/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/healthcare-resource-utilization-associated-with-tumor-induced-osteomalacia-review-of-patient-histories-prior-to-entry-in-clinical-trial-ux023t-cl201/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology